Streetbeat News

NANX

Nanophase Technologies Corp.

Employees

Industry

All Other Basic Organic Chemical Manufacturing

Open

1.97

Mkt cap

133M

Volume

22K

High

1.98

P/E Ratio

47.75

52-wk high

2.00

Low

1.90

Div yield

N/A

52-wk low

0.40

Insiders at Lumen Technologies, Nanophase Technologies, and Sunshine Biopharma have recently made significant stock purchases, signaling potential confidence in their companies' futures. Lumen Technologies reported better-than-expected Q4 results, Nanophase announced a rights offering, and Sunshine Biopharma posted a narrower quarterly loss.

Portfolio Pulse from Avi Kapoor

February 13, 2024 | 11:54 am

Nanophase Technologies (OTC:NANX) reported a larger loss in Q3 2023 with a GAAP EPS of $(0.03), down from $(0.02) in the same quarter last year. Sales also decreased by 17.78% to $7.96M from $9.68M in the previous year.

Portfolio Pulse from saritha@benzinga.com

November 13, 2023 | 9:25 pm

Insiders at four companies have recently made notable purchases of their own stocks. The CEO of 1847 Holdings (NYSE:EFSH) bought 75,000 shares, a 10% owner of Nanophase Technologies (OTC:NANX) acquired 85,847 shares, the COO of Kingstone Companies (NASDAQ:KINS) purchased 3,072 shares, and a director at Biodesix (NASDAQ:BDSX) bought 128,363 shares. These transactions may indicate the insiders' confidence in their companies' prospects.

Portfolio Pulse from Lisa Levin

August 24, 2023 | 12:53 pm

Nanophase Technologies (OTC:NANX) reported Q2 earnings of $0.01 per share, with sales of $11.87 million, marking a 5.79% increase from the same period last year.

Portfolio Pulse from vinayak@benzinga.com

August 04, 2023 | 12:11 pm

Insiders have been aggressively buying shares in Lexicon Pharmaceuticals, Heliogen, ImmunityBio, and Nanophase Technologies. This indicates their confidence in the companies' prospects and can be considered a factor for investors and traders interested in penny stocks.

Portfolio Pulse from Lisa Levin

June 06, 2023 | 1:22 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.